Theodore Darkow, PharmD

home / authors / theodore-darkow-pharmd

Articles

November 30th 2012

Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia

Theodore Darkow, PharmD J. Ross Maclean, MD Geoffrey F. Joyce, PhD Dana Goldman, PhD Darius N. Lakdawalla, PhD

July 15th 2005

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

Nicole M. Nitz, PhD Zhanna Jumadilova, MD, MBA Theodore Darkow, PharmD Jennifer R. Frytak, PhD Tamara Bavendam, MD

Latest Updated Articles

Transgender | Image credit: Olga Tsikarishvili - stock.adobe.com

Published: August 18th 2025 | Updated: August 25th 2025

Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults

Semaglutide | Image credit: Peter Hansen - stock.adobe.com

Published: August 19th 2025 | Updated: August 22nd 2025

Semaglutide Not Associated With Increased Risk of Eye Disorders

On-body delivery system | Image credit: Enable Injections

Published: June 6th 2025 | Updated: August 18th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

drug shortages in the US | Image credit: OntheRun Photo - stock.adobe.com

Published: June 27th 2025 | Updated: July 1st 2025

Report Reveals Mounting Burdens of Drug Shortages on US Health System

AJMC

Published: February 20th 2025 | Updated: February 21st 2025

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP

Hands holding pack of cigarettes | Image credit: Nopphon – stock.adobe.com

Published: January 16th 2025 | Updated: January 29th 2025

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions